scholarly journals Audiovestibular Manifestations in Autoimmune Disorders: A Case Clinical Control Study in Celiac Patients

2021 ◽  
Vol 31 (2) ◽  
pp. 34-38
Author(s):  
Nesrettin Turgut ◽  
Dilek Gülmez ◽  
Hasan Özdoğan
Keyword(s):  
Autoimmune Disorders ◽  
Clinical Control ◽  
Control Study

Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study

2010 ◽  
Vol 16 (7) ◽  
pp. 855-861 ◽  
Author(s):  
A. Langer-Gould ◽  
KB Albers ◽  
SK Van Den Eeden ◽  
LM Nelson
Keyword(s):  
Multiple Sclerosis ◽  
Case Control Study ◽  
Care Program ◽  
Population Based ◽  
Case Control ◽  
Autoimmune Disorders ◽  
Kaiser Permanente ◽  
Inflammatory Bowel ◽  
Clinical Records ◽  
Control Study

The objective of this study was to determine whether patients with multiple sclerosis (MS) are more likely to have other autoimmune disorders particularly prior to the diagnosis of MS. We conducted a population-based case—control study of patients enrolled in the Northern California Kaiser Permanente Medical Care Program. Electronic clinical records through 2005 were used to ascertain incident and prevalent MS cases and identify the presence and timing of 44 other diagnoses. Controls were matched 5:1 for gender, age, and Kaiser membership characteristics. We identified 5296 MS cases (including 924 diagnosed between 2001 and 2004) and 26,478 matched controls. Prior to MS diagnosis, cases were more likely than controls to have uveitis (OR = 3.2, 95%; CI 1.7—5.7), inflammatory bowel disease (IBD, OR = 1.7; 95%CI 1.2—2.5), and Bell’s palsy (OR = 3.2; 95%CI 1.2—8.3). Cases were also more likely to develop Guillain— Barré syndrome (GBS, OR = 5.0; 95%CI 1.6—15.4) and bullous pemphigoid (OR = 6.7; 95%CI 1.5—29.9). Cases were not more likely than controls to have or to develop rheumatoid arthritis, lupus or thyroiditis. MS may share environmental triggers, genetic susceptibilities and/or alterations in immune homeostasis with IBD and uveitis, but not with other autoimmune disorders.

scholarly journals Randomized clinical control study of locoregional therapy combined with arsenic trioxide for the treatment of hepatocellular carcinoma

Cancer ◽  
2015 ◽  
Vol 121 (17) ◽  
pp. 2917-2925 ◽  
Author(s):  
Hui Wang ◽  
Ying Liu ◽  
Xiu Wang ◽  
Donghui Liu ◽  
Zhiqiang Sun ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Arsenic Trioxide ◽  
Locoregional Therapy ◽  
Clinical Control ◽  
Control Study

scholarly journals A Randomised Clinical Control Study to Evaluate the Efficacy of Shodhita Kuchla Powder (Purified Strychnos Nux-Vomica L.) and Brahmi Extract (Bacopa Monnieri L. Pennell) on Klaibya (Dhwajbhang) w.s.r. to Erectile Dysfunction

AYUSHDHARA ◽  
2021 ◽  
pp. 3511-3523
Author(s):  
Deepak Verma ◽  
Ashwini Kumar Sharma ◽  
Megha Shukla
Keyword(s):  
Erectile Dysfunction ◽  
Sexual Activity ◽  
Laboratory Tests ◽  
Bacopa Monnieri ◽  
Initial Evaluation ◽  
Classical Text ◽  
Clinical Control ◽  
Group A ◽  
Group B ◽  
Control Study

Klaibya is defined in Ayurveda as the inability to achieve and maintain sufficient rigidity in the penis, which is essential for his sexual urges or the needs of his female partner during sexual activity. Chakrapani limits the concept of Klaibya to merely erectile dysfunction. Dhwajbhang, according to Acharya Sushruta, is a form of Klaibya caused by excessive coitus. The standard initial evaluation of a man experiencing ED is conducted in person and involves sexual, medical, and psychosocial histories, as well as laboratory tests comprehensive enough to identify comorbid diseases that may predispose the patient to ED and may contraindicate particular treatments. Properties of Ayurvedic drug; Kuchla (Strychnos nux-vomica) in classical text Rasatarangani as therapeutic of Klaibya (ED) and Brahmi (Bacopa monnieri) is well known Medhya drug that works on neuro- psychological disorders. The current study evaluated the effects of Kuchla and Brahmi on 36 erectile dysfunction patients, having 30 of them completing the trial. The patients were categorized into two parts: Group A administered an ED 250 capsule (Hypothetical) once a day (250mg) with milk, and Group B received a placebo once a day with milk HS for 30 days, followed by another 30 days.

scholarly journals Autoimmune Disease Prevalence in a Multiple Sclerosis Cohort in Argentina

2014 ◽  
Vol 2014 ◽  
pp. 1-3 ◽  
Author(s):  
Mauricio F. Farez ◽  
María E. Balbuena Aguirre ◽  
Francisco Varela ◽  
Alejandro A. Köhler ◽  
Jorge Correale
Keyword(s):  
Multiple Sclerosis ◽  
Autoimmune Disease ◽  
Latin American ◽  
Case Control Study ◽  
Case Control ◽  
Autoimmune Disorders ◽  
Disease Prevalence ◽  
Increased Risk ◽  
Increase Risk ◽  
Control Study

Background. Comorbid autoimmune diseases in MS patients have been studied extensively with controversial results. Moreover, no such data exists for Latin-American MS patients.Methods. We conducted a case-control study aimed to establish the prevalence of autoimmune disorders in a cohort of Argentinean MS patients.Results. There were no significant differences in autoimmune disease prevalence in MS patients with respect to controls. The presence of one or more autoimmune disorders did not increase risk of MS (OR 0.85, 95% CI 0.6–1.3).Discussion. Our results indicate absence of increased comorbid autoimmune disease prevalence in MS patients, as well as of increased risk of MS in patients suffering from other autoimmune disorders.

scholarly journals AN OPEN LABELLED CLINICAL CONTROL STUDY TO EVALUATE THE EFFICA-CY OF VIDANGADI ARKA NASYA IN THE MANAGEMENT OF ARDHAVABHEDA-KA (MIGRAINE WITHOUT AURA)

2020 ◽  
Vol 8 (10) ◽  
pp. 4742-4747
Author(s):  
Jeeva P ◽  
Veerayya R Hiremath ◽  
Shashikala K ◽  
Gururaj N
Keyword(s):  
Repeated Measures ◽  
Migraine Without Aura ◽  
Signs And Symptoms ◽  
Treatment Modalities ◽  
Current Line ◽  
Clinical Control ◽  
Group A ◽  
Bonferroni Test ◽  
Group B ◽  
Control Study

Background and Objective: Ardhavabhedaka (migraine without aura) is characterized by severe tearing, pricking and piercing pain in one half of the head and giddiness which develops suddenly after ten days or a fortnight. Based on signs and symptoms it may correlate with migraine characterized by half sided head-ache associated with nausea, vomiting, photophobia and phonophobia. The current line of management for migraine advocates the use of analgesics and antiemetics, vasoconstrictors, sumatriptan, topiramate, flunar-izine, Propranolol. Ayurveda emphasizes various treatment modalities of Ardhavabhedaka, includes both Shodhana and Shamana. Vidangadi avapeedana Nasya and Vidangadi arka (distillate) Nasya have been mentioned for ardhavabhedaka chikitsa. Arka is the essence of the drug; possesses laghu, ushna, kaphavatahara, increased potency, more shelf life, easy absorption and act fast. Materials and Methods: 20 patients of Group A were treated with Vidangadi Arka Nasya and Group B 20 patients were treated with Vidangadi Avapeedana Nasya (each nostril 6 drops for 7 days). Results: The data of both the groups were collected according to the objective and subjective Parameters and analyzed using repeated measures of ANOVA, Bonferroni test, and Mann- Whitney U Test. The efficacy was statistically highly significant with-in the group at P <0.001and statistically insignificant between the group at P >0.05 among all the parame-ters. Interpretation and Conclusion: Study can be concluded that patients treated with Vidangadi Arka and Avapeedana Nasya showed not much difference in the results statistically, clinically group A showed better results than group B.

Sign in / Sign up

Export Citation Format

Share Document